WAM
MLYS icon

Weiss Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Weiss Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$794K – 489
2025
Q1 		$794K Buy
+50,000
New +$575K 0.02% 203

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Weiss Asset Management's MLYS Position: Q2 2025 in Review

Weiss Asset Management sold out of Mineralys Therapeutics (MLYS) in Q2 2025, closing a stake of 50,000 shares — an estimated $794K sold.

Weiss Asset Management first reported a position in MLYS in Q1 2025 and held it in 1 quarter. The position peaked at $794K in Q1 2025. 165 funds tracked by Wall St. Rank hold MLYS as of Q2 2025.

  • Weiss Asset Management reported no remaining Mineralys Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Weiss Asset Management sold 50,000 Mineralys Therapeutics shares in Q2 2025, an estimated $794K.
  • Weiss Asset Management first reported a position in Mineralys Therapeutics in Q1 2025 and held it in 1 quarter.
  • Weiss Asset Management's Mineralys Therapeutics position peaked at $794K in Q1 2025.
  • 165 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2025.

Based on Weiss Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.